

10/525783

Application No. Not allotted yet
National Phase of PCT/SE2003/001352
Preliminary Amendment dated February 28, 2005 ✓

Amendments to the claims:

This listing of claims will replace all previous versions, and listings, of claims in this application.

Listing of Claims:

Claim 1 - 12 (Cancelled)

13.(New) A combination comprising:

a statin selected from atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin sodium, simvastatin or rosuvastatin, or a pharmaceutically-acceptable salt thereof and an $\alpha 7$ -nAChR agonist.

14.(New) A combination according to Claim 13 wherein said $\alpha 7$ -nAChR agonist is selected from spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidine]-2'-one,

(+)-spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidine]-2'-one,

(-)-spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidine]-2'-one,

spiro[1-azabicyclo[2.2.1]heptan-3,5'-oxazolidin-2'-one],

3'-methyl spiro-[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin-2'-one],

spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],

5'-bromospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],

5'-phenylspiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],

5'-nitrospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],

1'-chlorospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]isoquinoline],

5'-(phenylcarboxamido)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],

5'-(phenylaminocarbonylamino)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],

5'-(phenylsulfonylamido)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],

5'-aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 5'-N-methylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 5'-N,N-dimethylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-
 b]pyridine],
 5'-N,N-diethylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 5'-N-ethylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 5'-N-benzylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 5'-N-formamidospino[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 5'-N-acetamidospino[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]isoquinoline],
 spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]quinoline],
 5'-ethenylspiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 5'-(E)-(phenylethenyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-
 b]pyridine],
 5'-(4-morpholino)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 5'-(1-azetidiny)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 5'-(E)-(2-(4-pyridyl)ethenyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-
 b]pyridine],
 5'-(E)-(2-(2-pyridyl)ethenyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-
 b]pyridine],
 5'-(2-trimethylsilylethynyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-
 b]pyridine],
 5'-ethynylspiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 5'-(2-furyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 5'-(3-pyridyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 5'-methylspiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine-5'carbonitrile],
 spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine-5'carboxamide],
 5'-N'-(3-chlorophenyl)aminocarbonylminospino[1-azabicyclo[2.2.2]octane-3,2'-
 (3'H)-furo[2,3-b]pyridine],

5'-N'-(2-nitrophenyl)aminocarbonylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],

4'-chlorospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],

4'-methoxyspiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],

4'-phenylthiospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],

4'-(N-2-aminoethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],

4'-phenylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],

4'-methylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],

4'-(4-N-methylpiperazin-1-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],

4'-chloro-spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[3,2-c]pyridine],

spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[3,2-c]pyridine],

spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine-7'-oxide],

spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine-6'-carbonitrile],

6'-chlorospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],

6'-fluorospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],

N-(1-azabicyclo[2.2.2]oct-3-yl)(5-phenylfuran-2-carboxamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-fluorophenyl)furan-2-carboxamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-thienyl)benzamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(3-phenylbenzamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-pyridyl)benzamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(5-phenylthiophene-2-carboxamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-methoxyphenyl)benzamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(2-methoxyphenyl)benzamide),

~~N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-(N-acetylamino)phenyl)benzamide),~~

N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-fluorophenyl)benzamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-methylphenyl)benzamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(2-thienyl)benzamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3,5-dichlorophenyl)benzamide),

Rule
1,126

10/525183

Rule
1.126

N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(2-naphthyl)benzamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(4-fluorophenyl)benzamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-thienyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-benzo[b]furanyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-pyridyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-thienyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-methoxyphenyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-methoxyphenyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-fluorophenyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-naphthyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-methylphenyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-furyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-furyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-pyridyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-pyridyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-pyridyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(4-(2-pyridyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(4-(4-pyridyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(4-(3-pyridyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(*N*-acetylamino)phenyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-nitrophenyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-trifluoromethylphenyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-chlorophenyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(*N*-acetylamino)phenyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-fluorophenyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-methoxyphenyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-ethoxyphenyl)thiophene-2-carboxamide),

10/525783

N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3,5-dimethylisoxazol-4-yl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3,5-dimethylisoxazol-4-yl)thiophene-2-carboxamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-aminophenyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridyl)thiophene-3-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-chlorophenyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridyl)thiazole-3-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-pyridyl)thiazole-3-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(*N,N*-dimethylamino)phenyl)thiophene-2-carboxamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(8-quinoliny)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-phenylthiophene-3-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(4-phenylthiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-cyanophenyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(*N*-methylamino)phenyl)thiophene-2-carboxamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-hydroxyphenyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridylamino)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-chlorophenyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(4-morpholiny)phenyl)thiophene-2-carboxamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(aminomethyl)phenyl)thiophene-2-carboxamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(5-phenoxythiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-aminophenyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(*N,N*-dimethylamino)phenyl)furan-2-carboxamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-formylphenyl)thiophene-2-carboxamide); *N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(hydroxymethyl)phenyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-phenylfuran-2-carboxamide),

10/525783

Rule 1.126

(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-fluorophenyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-thienyl)benzamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-phenylbenzamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-pyridyl)benzamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-phenylthiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-methoxyphenyl)benzamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(2-methoxyphenyl)benzamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-(*N*-acetylamino)phenyl)benzamide);
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-fluorophenyl)benzamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-methylphenyl)benzamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(2-thienyl)benzamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3,5-dichlorophenyl)benzamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(2-naphthyl)benzamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(4-fluorophenyl)benzamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-thienyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-benzo[b]furan-2-yl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-pyridyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-thienyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-methoxyphenyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-methoxyphenyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-fluorophenyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-naphthyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-methylphenyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-furyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-furyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-pyridyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-pyridyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-pyridyl)thiophene-2-carboxamide),

10/525783

Rule 1.126

(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(4-(2-pyridyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(4-(4-pyridyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(4-(3-pyridyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(*N*-acetylamino)phenyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-nitrophenyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-trifluoromethylphenyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-chlorophenyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(*N*-acetylamino)phenyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-fluorophenyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-methoxyphenyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-ethoxyphenyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3,5-dimethylisoxazol-4-yl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3,5-dimethylisoxazol-4-yl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-aminophenyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridyl)thiophene-3-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)[5-(4-chlorophenyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridyl)thiazole-3-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-pyridyl)thiazole-3-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(*N,N*-dimethylamino)phenyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(8-quinoliny)thiophene-2-carboxamide),
(*S*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridyl)thiophene-2-carboxamide);
(*S*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-pyridyl)thiophene-2-carboxamide),
(*S*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-pyridyl)thiophene-2-carboxamide),
(*S*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-phenylthiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-phenylthiophene-3-carboxamide),

2006
1.126

(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(4-phenylthiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-cyanophenyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(*N*-methylamino)phenyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-aza-bicyclo[2.2.2]oct-3-yl)(5-(3-hydroxyphenyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridylamino)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-chlorophenyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(4-morpholinyl)phenyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(aminomethyl)phenyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-phenoxythiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-aminophenyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(*N,N*-dimethylamino)phenyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-formylphenyl)thiophene-2-carboxamide), or
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(hydroxymethyl)phenyl)thiophene-2-carboxamide), or a pharmaceutically-acceptable salt thereof.

15.(New) A combination according to Claim 13, wherein said statin is rosuvastatin or a pharmaceutically-acceptable salt thereof and

said $\alpha 7$ -nAChR agonist is selected from:

spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidine]-2'-one;

N-(1-Azabicyclo[2.2.2]oct-3-yl)[*E*-3-(2-thienyl)propenamide], or

(2'*R*)-5'-(3-furanyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'*H*)-furo[2,3-*b*]pyridine] or

a pharmaceutically-acceptable salt thereof.

16.(New) A pharmaceutical composition comprising a combination according to Claim 13 together with a pharmaceutically acceptable diluent or carrier.

10/525783

Rule 1.126
17.(New) A method providing neuroprotection or analgesia for the treatment or prophylaxis of a condition or disorder involving reduced cholinergic function selected from Alzheimer's disease, cognitive or attention disorders, anxiety, depression, smoking cessation, schizophrenia, Tourette's syndrome, and Parkinson's disease which method comprises administering to a patient suffering therefrom a therapeutically effective amount of a pharmaceutical composition as defined in Claim 16.

18.
18.(New) The method according to Claim 16, for treatment or prophylaxis of Alzheimer's disease.

19.
18.(New) A method providing neuroprotection or analgesia for treatment or prophylaxis of a condition or disorder involving reduced cholinergic function selected from Alzheimer's disease, cognitive or attention disorders, anxiety, depression, smoking cessation, schizophrenia, Tourette's syndrome, and Parkinson's disease which method comprises administering to a patient suffering therefrom a therapeutically effective amount of a combination as defined in Claim 13.

20.
19.(New) A method for the treating a condition or disorder involving reduced cholinergic function selected from Alzheimer's disease, cognitive or attention disorders, anxiety, depression, smoking cessation, schizophrenia, Tourette's syndrome, and Parkinson's disease which method comprises administering to a patient suffering therefrom a therapeutically effective amount of a a statin selected from atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin sodium, simvastatin or rosuvastatin, or a pharmaceutically-acceptable salt thereof and
an $\alpha 7$ -nAChR agonist.

21.
20.(New) The method according to Claim 19, for treatment or prophylaxis of Alzheimer's disease.

10/525783

22
21

(New) The method according to Claim 19, wherein said statin is rosvastatin or a pharmaceutically-acceptable salt thereof and said $\alpha 7$ -nAChR agonist is selected from:

spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidine]-2'-one;

N-(1-Azabicyclo[2.2.2]oct-3-yl)[*E*-3-(2-thienyl)propenamide], or

(2'R)-5'-(3-furanyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine] or

a pharmaceutically-acceptable salt thereof.

Rule
1.126